Filing summary
Issuer discrepancy: The request identifies Madrigal Pharmaceuticals, Inc., but the supplied filing is Synta Pharmaceuticals Corp.’s Form 10-Q. This summary reflects the supplied filing, for the unaudited quarter ended March 31, 2013, compared with the quarter ended March 31, 2012 where applicable.
Business context
Synta is a clinical-stage biopharmaceutical company developing small-molecule drug candidates, primarily for cancer and inflammatory diseases. It reported no product revenue and had two clinical-stage oncology programs and additional preclinical programs. The company stated that it retained full ownership of its drug candidates.
Financial results and liquidity
- Revenue: $0 in Q1 2013, versus $147,000 in Q1 2012, which was grant revenue. The company had no product sales.
- Expenses and loss: Research and development expense was $16.4 million, up 36%; general and administrative expense was $3.9 million, up 44%. Operating loss was $20.3 million, compared with $14.6 million. Net loss was $20.7 million, or $0.30 per share, versus $15.1 million, or $0.27 per share.
- Cash flow: Operating activities used $22.2 million, versus $15.3 million. Investing activities used $36.6 million, primarily reflecting purchases of marketable securities; financing activities provided $12.3 million. Cash and cash equivalents declined $46.6 million during the quarter to $35.0 million.
- Liquidity: Cash, cash equivalents and marketable securities totaled $90.4 million at March 31, 2013, versus $100.6 million at December 31, 2012. Working capital was $75.3 million.
- Debt: Term loans were $23.6 million in total at March 31, 2013. In March, Synta obtained additional GECC loan funding; the GECC principal balance rose to $22.5 million. Its interest rate remained 9.75%, with interest-only payments scheduled through December 2013 and principal-and-interest installments beginning January 2014. Oxford loan interest was 13.35%. The GECC loan is secured by substantially all company assets except intellectual property, subject to a springing lien provision.
- Margins: Product gross margin is not applicable because Synta reported no product revenue.
Material changes and developments
- R&D expense increased $4.3 million year over year, mainly from a $5.6 million increase in ganetespib program costs, including GALAXY-2 start-up and clinical pharmacology work. Spending on elesclomol and CRACM declined.
- G&A expense rose $1.2 million, reflecting higher personnel-related costs and external professional fees.
- Financing included $13.2 million in additional term-loan proceeds and approximately $1.0 million from option exercises. Synta also had an at-the-market facility permitting up to $28 million of stock sales, but reported no sales under it to date.
- The company reported an accumulated deficit of $481.9 million. Common shares outstanding were 69,129,951 at March 31, 2013.
Outlook, clinical programs and risks
- Management expected operating losses and cash use to continue, with ganetespib R&D spending and G&A costs expected to rise in 2013. Based on then-current operating levels and assumptions about planned activities, Synta expected its cash resources to fund operations into the second quarter of 2014. Management cautioned that additional funding might be needed sooner.
- GALAXY-1 interim results in NSCLC adenocarcinoma showed median overall survival not reached in the ganetespib-plus-docetaxel arm versus 7.4 months for docetaxel alone; reported progression-free survival was 4.2 versus 2.8 months and response rates were 16% versus 8%. These were interim results, with reported p-values of 0.183 for overall survival in the all-patient database, 0.076 for progression-free survival and 0.078 for response rate. The filing described the findings as supporting further study; they do not establish confirmatory benefit.
- GALAXY-2 enrollment began in April 2013. Management projected interim and final analyses in 2014. GALAXY-1 follow-up analyses were expected in 2013. These were projections, not reported outcomes.
- Clinical development, regulatory review, trial enrollment, safety and efficacy, financing availability, and the ability to secure partnerships are substantial uncertainties. Synta said it had preliminary partnership discussions but no assurance of agreements or funding. It reported no material changes to its previously disclosed risk factors and no material legal proceedings.
Key facts for investors to verify
- Confirm issuer identity: the supplied filing is Synta’s, not Madrigal’s.
- Verify the stated cash runway against actual operating burn, clinical-trial costs and financing needs.
- Review subsequent GALAXY-1 and GALAXY-2 results, including statistical significance, trial design and safety data.
- Assess the GECC and Oxford debt terms, scheduled repayments, covenants and collateral provisions.
- Check whether Synta later obtained partnership or capital-markets funding, including use of its at-the-market facility.